Literature DB >> 23247425

[Onset of a fulminant malignant hyperthermia crisis. Case report of a 74-year-old patient with previously subclinical central core disease].

M Wejbora1, H Bornemann-Cimenti, D Lessel, C Mandl, H Voit-Augustin, G Schwarz.   

Abstract

Malignant hyperthermia (MH) is a latent, autosomal dominant inherited syndrome of skeletal musculature which results in excessive hypermetabolism induced by halogenated anesthetic agents and depolarizing muscle relaxants and is caused by an uncontrolled intramuscular calcium release. This case report focuses on the description of symptoms of a fulminant MH crisis. A possible link between central core disease (CCD) and the clinical severity of MH crisis is postulated in this paper.

Entities:  

Mesh:

Year:  2012        PMID: 23247425     DOI: 10.1007/s00101-012-2107-0

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  10 in total

Review 1.  [Malignant hyperthermia. General, clinical and experimental aspects].

Authors:  M Steinfath; F Wappler; J Scholz
Journal:  Anaesthesist       Date:  2002-04       Impact factor: 1.041

2.  Case scenario: Increased end-tidal carbon dioxide: a diagnostic dilemma.

Authors:  Timothy J Tautz; Albert Urwyler; Joseph F Antognini; Bruno Riou
Journal:  Anesthesiology       Date:  2010-02       Impact factor: 7.892

Review 3.  Mutations in RYR1 in malignant hyperthermia and central core disease.

Authors:  Rachel Robinson; Danielle Carpenter; Marie-Anne Shaw; Jane Halsall; Philip Hopkins
Journal:  Hum Mutat       Date:  2006-10       Impact factor: 4.878

4.  Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group.

Authors:  K P E Glahn; F R Ellis; P J Halsall; C R Müller; M M J Snoeck; A Urwyler; F Wappler
Journal:  Br J Anaesth       Date:  2010-10       Impact factor: 9.166

5.  Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease.

Authors:  J Tong; H Oyamada; N Demaurex; S Grinstein; T V McCarthy; D H MacLennan
Journal:  J Biol Chem       Date:  1997-10-17       Impact factor: 5.157

6.  RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.

Authors:  Rachel L Robinson; Collin Brooks; Sarah L Brown; F Richard Ellis; P Jane Halsall; Rupert J Quinnell; Marie-Anne Shaw; Philip M Hopkins
Journal:  Hum Mutat       Date:  2002-08       Impact factor: 4.878

7.  Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006.

Authors:  Marilyn Green Larach; Gerald A Gronert; Gregory C Allen; Barbara W Brandom; Erik B Lehman
Journal:  Anesth Analg       Date:  2010-02-01       Impact factor: 5.108

Review 8.  Malignant hyperthermia.

Authors:  M Denborough
Journal:  Lancet       Date:  1998-10-03       Impact factor: 79.321

9.  Malignant hyperthermia.

Authors:  Norman J Halliday
Journal:  J Craniofac Surg       Date:  2003-09       Impact factor: 1.046

10.  A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group.

Authors: 
Journal:  Br J Anaesth       Date:  1984-11       Impact factor: 9.166

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.